Myostatin is a novel tumoral factor that induces cancer cachexia

Biochemical Journal

Volumn 446, Issue 1, 2012, Pages 23-36

  Lokireddy, Sudarsanareddy ^a   Wijesoma, Isuru Wijerupage ^a   Bonala, Sabeera ^a   Wei, Meng ^a   Sze, Siu Kwan ^a   McFarlane, Craig ^b   Kambadur, Ravi ^a,b   Sharma, Mridula ^c  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Activin receptor type II B; Autophagy lysosome system; Myostatin; Nuclear factor B (NF B); Reactive oxygen species (ROS); Skeletal muscle wasting; Tumoral factor; Ubiquitin proteasome system

Indexed keywords

ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR TYPE II B; ATROGIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUSCLE RING FINGER 1 PROTEIN; MYOSTATIN; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CACHEXIA; CANCER CELL; CELL CULTURE; COLON CANCER CELL; CONTROLLED STUDY; LYSOSOME; MITOCHONDRION; MOUSE; MUSCLE ATROPHY; MUSCLE CELL; MYOTUBE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SKELETAL MUSCLE; SKELETAL MUSCLE WASTING; UPREGULATION;

ACTIVIN RECEPTORS, TYPE II; ACTIVINS; ANIMALS; AUTOPHAGY; CACHEXIA; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CULTURE MEDIA, CONDITIONED; HUMANS; LYSOSOMES; MICE; MICE, INBRED STRAINS; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MYOBLASTS, SKELETAL; MYOSTATIN; NF-KAPPA B; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

MUS;

EID: 84864762337     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20112024     Document Type: Article

References (46)

1. Tisdale, M. J. (2009) Mechanisms of cancer cachexia. Physiol. Rev. 89, 381-410
2. Tisdale, M. J. (2005) Molecular pathways leading to cancer cachexia. Physiology 20, 340-348
3. Tisdale, M. J. (2005) The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. J. Support. Oncol. 3, 209-217
4. Fearon, K. C. (2008) Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur. J. Cancer 44, 1124-1132
5. Lokireddy, S., McFarlane, C., Ge, X., Zhang, H., Sze, S. K., Sharma, M. and Kambadur, R. (2011) Myostatin induces degradation of sarcomeric proteins through a Smad3 signaling mechanism during skeletal muscle wasting. Mol. Endocrinol. 25, 1936-1949
6. Lokireddy, S., Mouly, V., Butler-Browne, G., Gluckman, P. D., Sharma, M., Kambadur, R. and McFarlane, C. (2011) Myostatin promotes the wasting of human myoblast cultures through promoting ubiquitin-proteasome pathway-mediated loss of sarcomeric proteins. Am. J. Physiol. Cell Physiol. 301, C1316-C1324
7. Clarke, B. A., Drujan, D., Willis, M. S., Murphy, L. O., Corpina, R. A., Burova, E., Rakhilin, S. V., Stitt, T. N., Patterson, C., Latres, E. and Glass, D. J. (2007) The E3 ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 6, 376-385 (Pubitemid 350011998)
8. Cohen, S., Brault, J. J., Gygi, S. P., Glass, D. J., Valenzuela, D. M., Gartner, C., Latres, E. and Goldberg, A. L. (2009) During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. 185, 1083-1095
9. Glass, D. J. (2005) Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 37, 1974-1984
10. Tisdale, M. J. (2009) Cancer cachexia. Curr. Opin. Gastroenterol. 26, 146-151
11. Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H. and Goldberg, A. L. (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399-412 (Pubitemid 38534545)
12. Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W. S. et al. (2010) Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531-543
13. Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J. and Yancopoulos, G. D. (2001) Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3, 1014-1019 (Pubitemid 34428747)
14. Cai, D., Frantz, J. D., Tawa, Jr, N. E., Melendez, P. A., Oh, B. C., Lidov, H. G., Hasselgren, P. O., Frontera, W. R., Lee, J., Glass, D. J. and Shoelson, S. E. (2004) IKKβ /NF-κB activation causes severe muscle wasting in mice. Cell 119, 285-298 (Pubitemid 39360909)
15. Acharyya, S. and Guttridge, D. C. (2007) Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin. Cancer Res. 13, 1356-1361 (Pubitemid 46450422)
16. Acharyya, S., Ladner, K. J., Nelsen, L. L., Damrauer, J., Reiser, P. J., Swoap, S. and Guttridge, D. C. (2004) Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J. Clin. Invest. 114, 370-378 (Pubitemid 39071609)
17. Bakkar, N. and Guttridge, D. C. (2010) NF-κ B signaling: a tale of two pathways in skeletal myogenesis. Physiol. Rev. 90, 495-511
18. McFarlane, C., Plummer, E., Thomas, M., Hennebry, A., Ashby, M., Ling, N., Smith, H., Sharma, M. and Kambadur, R. (2006) Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κ B-independent, Fox01-dependent mechanism. J. Cell. Physiol. 209, 501-514 (Pubitemid 44484641)
19. Benny Klimek, M. E, Aydogdu, T., Link, M. J., Pons, M., Koniaris, L. G. and Zimmers, T. A. (2010) Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391, 1548-1554
20. Sengupta, A., Molkentin, J. D. and Yutzey, K. E. (2009) FoxO transcription factors promote autophagy in cardiomyocytes. J. Biol. Chem. 284, 28319-28331
21. Cosper, P. F. and Leinwand, L. A. (2011) Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner. Cancer Res. 71, 1710-1720
22. McFarlane, C., Langley, B., Thomas, M., Hennebry, A., Plummer, E., Nicholas, G., McMahon, C., Sharma, M. and Kambadur, R. (2005) Proteolytic processing of myostatin is auto-regulated during myogenesis. Dev. Biol. 283, 58-69 (Pubitemid 40828842)
23. Meng, W., Zhang, H., Guo, T., Pandey, C., Zhu, Y., Kon, O. L. and Sze, S. K. (2008) One-step procedure for peptide extraction from in-gel digestion sample for mass spectrometric analysis. Anal. Chem. 80, 9797-9805
24. Langley, B., Thomas, M., Bishop, A., Sharma, M., Gilmour, S. and Kambadur, R. (2002) Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J. Biol. Chem. 277, 49831-49840 (Pubitemid 36014431)
25. Ge, X., McFarlane, C., Vajjala, A., Lokireddy, S., Ng, Z. H., Tan, C. K., Tan, N. S., Wahli, W., Sharma, M. and Kambadur, R. (2011) Smad3 signaling is required for satellite cell function and myogenic differentiation of myoblasts. Cell Res. 21, 1591-1604
26. Driscoll, J. and Goldberg, A. L. (1990) The proteasome (multicatalytic protease) is a component of the 1500-kDa proteolytic complex which degrades ubiquitin-conjugated proteins. J. Biol. Chem. 265, 4789-4792
27. Hershko, A. (1988) Ubiquitin-mediated protein degradation. J. Biol. Chem. 263, 15237-15240
28. Palomero, J., Pye, D., Kabayo, T., Spiller, D. G. and Jackson, M. J. (2008) In situ detection and measurement of intracellular reactive oxygen species in single isolated mature skeletal muscle fibers by real time fluorescence microscopy. Antioxid. Redox Signaling 10, 1463-1474
29. Chen, H., Vermulst, M., Wang, Y. E., Chomyn, A., Prolla, T. A., McCaffery, J. M. and Chan, D. C. (2010) Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations. Cell 141, 280-289
30. Chan, C. Y., Masui, O., Krakovska, O., Belozerov, V. E., Voisin, S., Ghanny, S., Chen, J., Moyez, D., Zhu, P., Evans, K. R. et al. (2011) Identification of differentially regulated secretome components during skeletal myogenesis. Mol. Cell. Proteomics. 10, M110. 004804
31. Henningsen, J., Rigbolt, K. T., Blagoev, B., Pedersen, B. K. and Kratchmarova, I. (2010) Dynamics of the skeletal muscle secretome during myoblast differentiation. Mol. Cell. Proteomics 9, 2482-2496
32. McCroskery, S., Thomas, M., Maxwell, L., Sharma, M. and Kambadur, R. (2003) Myostatin negatively regulates satellite cell activation and self-renewal. J. Cell Biol. 162, 1135-1147 (Pubitemid 37174195)
33. Seoane, J., Le, H. V., Shen, L., Anderson, S. A. and Massague, J. (2004) Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117, 211-223 (Pubitemid 38496241)
34. Guttridge, D. C. (2004) Signaling pathways weigh in on decisions to make or break skeletal muscle. Curr. Opin. Clin. Nutr. Metab. Care 7, 443-450
35. Arthur, P. G., Grounds, M. D. and Shavlakadze, T. (2008) Oxidative stress as a therapeutic target during muscle wasting: considering the complex interactions. Curr. Opin. Clin. Nutr. Metab. Care 11, 408-416
36. Sriram, S., Subramanian, S., Sathiakumar, D., Venkatesh, R., Salerno, M. S., McFarlane, C. D., Kambadur, R. and Sharma, M. (2011) Modulation of reactive oxygen species in skeletal muscle by myostatin is mediated through NF-κB. Aging Cell 10, 931-948
37. Chen, Y., Azad, M. B. and Gibson, S. B. (2009) Superoxide is the major reactive oxygen species regulating autophagy. Cell Death Differ. 16, 1040-1052
38. Kowaltowski, A. J., de Souza-Pinto, N. C., Castilho, R. F. and Vercesi, A. E. (2009) Mitochondria and reactive oxygen species. Free Radical Biol. Med. 47, 333-343
39. Karbowski, M., Neutzner, A. and Youle, R. J. (2007) The mitochondrial E3 ubiquitin ligase MARCH5 is required for Drp1 dependent mitochondrial division. J. Cell Biol. 178, 71-84 (Pubitemid 47026403)
40. Li, W., Bengtson, M. H., Ulbrich, A., Matsuda, A., Reddy, V. A., Orth, A., Chanda, S. K., Batalov, S. and Joazeiro, C. A. (2008) Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PLoS ONE 3, e1487
41. Waddell, D. S., Baehr, L. M., van den Brandt, J., Johnsen, S. A., Reichardt, H. M., Furlow, J. D. and Bodine, S. C. (2008) The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am. J. Physiol. Endocrinol. Metab. 295, 785-797
42. McFarlane, C., Sharma, M. and Kambadur, R. (2008) Myostatin is a procachectic growth factor during postnatal myogenesis. Curr. Opin. Clin. Nutr. Metab. Care 11, 422-427
43. Langley, B., Thomas, M., McFarlane, C., Gilmour, S., Sharma, M. and Kambadur, R. (2004) Myostatin inhibits rhabdomyosarcoma cell proliferation through an Rb-independent pathway. Oncogene 23, 524-534 (Pubitemid 38175007)
44. Romanello, V., Guadagnin, E., Gomes, L., Roder, I., Sandri, C., Petersen, Y., Milan, G., Masiero, E., Del Piccolo, P., Foretz, M. et al. (2010) Mitochondrial fission and remodelling contributes to muscle atrophy. EMBO J. 29, 1774-1785
45. Wang, K. and Klionsky, D. J. (2011) Mitochondria removal by autophagy. Autophagy 7, 297-300
46. Youle, R. J. and Narendra, D. P. (2011) Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 12, 9-14